[EN] TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS [FR] DÉRIVÉS TRICYCLIQUES DE 2,4-DIAMINO-L,3,5-TRIAZINE UTILES POUR LE TRAITEMENT DU CANCER ET DE TROUBLES MYÉLOPROLIFÉRATIFS
[EN] TRICYCLIC 2,4-DIAMIN0-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS [FR] DÉRIVÉS TRICYCLIQUES DE 2,4-DIAMINO-L,3,5-TRIAZINE UTILES POUR LE TRAITEMENT DU CANCER ET DE TROUBLES MYÉLOPROLIFÉRATIFS
[EN] 2-(IMIDAZOLYLAMINO)-PYRIDINE DERIVATIVES AND THEIR USE AS JAK KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE 2-(IMIDAZOLYLAMINO)-PYRIDINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA JAK KINASE
申请人:ASTRAZENECA AB
公开号:WO2010020810A1
公开(公告)日:2010-02-25
The present inv ention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein Ring A is 5- or 6-membered heteroaryl, wherein said 5- or 6-membered heteroaryl is optionally substituted on carbon with one or more R6, and wherein if said 5- or 6- membcred heteroaryl contains an -NH- moiety, that -NH- moiety is optionally substituted with R6; D is selected from N and C-R3; E is selected from N and C-R4, wherein at least one of D and E is carbon; X is selected from -NH-, -O-, and -S-; and to their pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
[EN] HETEROCYCLIC JAK KINASE INHIBITORS<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE LA KINASE JAK
申请人:ASTRAZENECA AB
公开号:WO2010038060A1
公开(公告)日:2010-04-08
The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
[EN] P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN<br/>[FR] ANTAGONISTES DU RÉCEPTEUR P2X3 UTILISÉS DANS LE TRAITEMENT DE LA DOULEUR
申请人:MERCK & CO INC
公开号:WO2009058299A1
公开(公告)日:2009-05-07
The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
TRICYCLIC 2,4-DIAMINO-L,3,5-TRIAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF CANCER AND MYELOPROLIFERATIVE DISORDERS
申请人:Almeida Lynsie
公开号:US20110183954A1
公开(公告)日:2011-07-28
The present invention relates to compounds of Formula (I): (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.
The present invention relates to compounds of Formula (I) and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds provide a treatment for myeloproliferative disorders and cancer.